AMLX Stock Recent News

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.65 per share a year ago.

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.

Amylyx Therapeutics shares have limited downside ahead of a Phase 3 trial of Relyvrio, an ALS treatment candidate, according to Baird. Analysts have initiated coverage on the stock with an Outperform rating and a $37 price target.

Amylyx (AMLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amylyx Pharmaceuticals is a biotech company that develops treatments for neurodegenerative diseases, with its product AMX0035 approved by the FDA for ALS therapy. The company's Phase III clinical trials for AMX0035 are expected to yield results in mid-2024, and it plans to seek approval in the EU if the results are satisfactory. AMLX expects to expand the usage of its medication Relyvrio to at least 10,000 patients, leading to significant revenue growth.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Josh Cohen - Co-CEO & Co-Founder Justin Klee - Co-CEO & Co-Founder Margaret Olinger - Chief Commercial Officer James Frates - Chief Financial Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Geoff Meacham - Bank of America Umer Raffat - Evercore ISI Marc Goodman - Leerink Partners Graig Suvannavejh - Mizuho Partners Ananda Ghosh - H.C. Wainwright & Co. Operator Good morning.

Amylyx Pharmaceuticals shares fell Friday after its ALS (amyotrophic lateral sclerosis) drug was denied marketing authorization by European Union regulators for the second time.  The repeat rebuff comes after Amylyx asked in June for a formal re-examination of the original denial adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative opinion on Albrioza, a treatment for amyotrophic lateral sclerosis. The decision comes after a re-examination of the initial negative opinion issued in June.